Navigation Links
InspireMD to Ring Opening Bell at New York Stock Exchange on Thursday, October 24th
Date:10/23/2013

BOSTON, Oct. 23, 2013 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will ring the Opening Bell at the New York Stock Exchange on Thursday, October 24, 2013 at 9:30 a.m. ET.

Representing the Company, Alan Milinazzo, Chief Executive Officer, and Craig Shore, Chief Financial Officer, will be joined by members of the InspireMD management team to ring the Opening Bell.

"We look forward to ringing the Opening Bell at the New York Stock Exchange as we celebrate the progress made by the Company over the past year," said Alan Milinazzo, Chief Executive Officer of InspireMD.  "Over the next year, we are looking forward to several exciting milestones within our clinical and product development programs, as well as for our commercialization operations.  This includes the announcement next week of 12-month follow-up data for the MASTER trial in San Francisco at the Transcatheter Cardiovascular Therapeutics (TCT) Conference on October 29th."

A live webcast of the NYSE Opening Bell Ceremony will be available online at:
https://nyse.nyx.com/the-bell/todays-bells-live.

A replay of the NYSE Opening Bell Ceremony and photos from the event will be available at:
www.Inspire-MD.com or https://exchanges.nyx.com/new-york-stock-exchange-0.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuard™ technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures.  InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard™ EPS is CE Mark approved. It is not approved for sale in the U.S. by the FDA at this time.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com

Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: 212-896-1216 / 212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com


'/>"/>
SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
2. InspireMD Appoints David Blossom as Vice President of Global Marketing and Strategy
3. InspireMD Announces Participation in Two Investor Conferences in September
4. InspireMD Completes First Phase of Manufacturing Upgrade and Partners with HealthLink for Global Logistics and Distribution Services
5. InspireMDs MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
6. InspireMD Reports Financial Results For Period Ended March 31, 2013
7. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
8. InspireMD Closes $25 Million Underwritten Public Offering
9. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
10. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
11. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
Breaking Medicine Technology:
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... Yesterday, the ... KKK by saying there are two sides. There are not two sides to hatred, ... to rationalize violence and prejudice, and the NPEIV stands against all forms of such ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! God’s Gift: A Story ... parents and God. “Congratulations! It's A Boy! God’s Gift: A Story of Love” is ... Island, New York. , Published by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s ...
(Date:8/18/2017)... (PRWEB) , ... ... ... For Immediate ... Polling Shows Young Women Seek Sex and Relationship Advice from ...
(Date:8/18/2017)... ... August 18, 2017 , ... August 18, 2017 — ... advocating for active, healthy lifestyles and highlighting the importance of proactive eye and ... impairments and shares the latest innovations in hearing aid technology. , According ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, ... new charity drive to generate community support for efforts to educate the local population ... treatments for all types of cancer. , Each day in America, roughly 4,600 ...
Breaking Medicine News(10 mins):